燃石医学上涨2.53%，报9.535美元/股，总市值1.03亿美元

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.53% on August 22, reaching $9.535 per share, with a total market capitalization of $103 million [1] - As of March 31, 2025, the total revenue of Burning Stone Medical is projected to be 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company is expected to be -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [2] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - In July 2018, the company received the first certification for NGS testing kits for cancer from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States; the laboratory in California has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]